Systemic Lupus Erythematosus Management

Introduction to SLE Management

The American College of Rheumatology recommends hydroxychloroquine at ≤5 mg/kg actual body weight (typically 200-400 mg daily) for all SLE patients, unless contraindicated, as it reduces disease activity, prevents flares, improves survival, and provides cardiovascular and metabolic benefits 1, 2
Ophthalmological screening is mandatory at baseline, after 5 years, and yearly thereafter to monitor for retinal toxicity 1

The primary objective is achieving complete remission or low disease activity, not merely symptom control, according to the European League Against Rheumatism 2
Disease activity must be assessed at every visit using validated indices (SLEDAI, BILAG, ECLAM) 3, 4, 5
The treatment goals include preventing organ damage and flares, with comparable outcomes for both remission and low disease activity states 2

For organ-threatening manifestations, administer IV methylprednisolone 500-2500 mg total (250-1000 mg/day for 1-3 days) followed by oral prednisone 0.3-0.5 mg/kg/day, as recommended by the American College of Rheumatology 2
IV methylprednisolone pulses provide immediate therapeutic effect and enable lower starting doses of oral glucocorticoids 4, 1
The initial oral dose of 0.3-0.5 mg/kg/day is lower than historical recommendations based on recent evidence showing comparable efficacy with reduced toxicity 2

When disease cannot be controlled with hydroxychloroquine and low-dose glucocorticoids alone, add methotrexate, azathioprine, or mycophenolate mofetil as first-line immunosuppressive agents, as suggested by the European League Against Rheumatism 4, 1, 2
Methotrexate is preferred for skin and joint manifestations 4
Azathioprine is particularly suitable for women contemplating pregnancy 4
Mycophenolate mofetil is effective for both renal and non-renal manifestations (except neuropsychiatric disease) 4

First-line induction therapy consists of mycophenolate mofetil 2-3 g/day OR low-dose IV cyclophosphamide (500 mg every 2 weeks × 6 doses) combined with IV methylprednisolone 500-2500 mg total followed by oral prednisone 0.3-0.5 mg/kg/day, according to the American College of Rheumatology 2
Both mycophenolate and low-dose cyclophosphamide show similar efficacy; mycophenolate may be more effective in African-Americans 2
High-dose IV cyclophosphamide (0.5-0.75 g/m² monthly × 6 months) is reserved for patients with adverse prognostic factors including crescents/necrosis in >25% glomeruli or GFR 25-80 mL/min 2

Treatment depends on the underlying pathophysiological mechanism: for inflammatory mechanisms, use high-dose glucocorticoids plus cyclophosphamide; for thrombotic/embolic mechanisms, use anticoagulation with warfarin, as recommended by the American College of Rheumatology 4, 1
High-dose glucocorticoids (IV methylprednisolone) combined with cyclophosphamide showed response in 18/19 patients compared to 7/13 with methylprednisolone alone (p=0.03) 1

Monitor disease activity at every visit (every 3 months for stable patients, more frequently for uncontrolled disease) including anti-dsDNA, C3, C4, complete blood count, creatinine, proteinuria, and urine sediment, as suggested by the European League Against Rheumatism 6, 8, 1
SLE patients have a 5-fold increased mortality risk and require systematic screening for infections, cardiovascular disease, hypertension, diabetes, dyslipidemia, osteoporosis, and malignancies (especially non-Hodgkin lymphoma) 4, 1
Low-dose aspirin should be considered for patients with antiphospholipid antibodies, those receiving corticosteroids, or those with cardiovascular risk factors 1
Calcium and vitamin D supplementation is mandatory for all patients on long-term glucocorticoids 4, 1, 5

Safe medications during pregnancy include prednisolone, azathioprine, hydroxychloroquine, and low-dose aspirin; mycophenolate mofetil, cyclophosphamide, and methotrexate are absolutely contraindicated, as recommended by the American College of Rheumatology 4, 1
Pregnancy may increase lupus disease activity, but flares are usually mild 4
Patients with lupus nephritis and antiphospholipid antibodies require closer monitoring for pre-eclampsia 4

Photo-protection with sunscreens is mandatory for all patients to prevent cutaneous flares, as suggested by the European League Against Rheumatism 4, 1
Lifestyle modifications including smoking cessation, weight control, and exercise improve patient outcomes 4
NSAIDs may be used judiciously for limited periods in patients at low risk for complications 4